Drugs / Solbinsiran
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04644809 | Nov 2020 → May 2022 | hyperlipidemia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT07269210 | Dec 2025 → Mar 2027 expected | — | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT05256654 | Jul 2022 → Mar 2024 | hyperlipidemia, hyperlipoproteinemia | Eli Lilly and Company | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Solbinsiran | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07269210 ↗ |
| Known as | LY3561774 | “A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia” NCT07269210 ↗ |
| Route | Subcutaneous | “Participants will receive solbinsiran subcutaneously (SC)” NCT07269210 ↗ |